Why Did Viking Therapeutics Stock Jump?

VKTXYTD-16.9%SPYYTD+11.5%XLVYTD+23.5%
Analyze VKTX →

For questions about this article or underlying research, email help@trefis.com.

Viking Therapeutics (VKTX) stock rose 5.9% on Friday, November 13, 2026, while the S&P 500 fell 0.4%. The company released no announcement, earnings report or filing around the move, and its biotechnology sub-industry finished the day flat, recording a median change of -0.1% across 78 other companies. So what else was happening in the market that Friday, and where does Viking fit in it?

Image from Pixabay

What Was The Market Doing As Viking Rose?

Selling pressure hit the broader market that Friday. The Nasdaq Composite dropped 0.9% from Thursday’s close, while AI stocks slid again as turmoil around Nvidia rattled the sector.

Viking operates far from that trade. The drug developer has no sales yet, reporting no revenue over the four quarters to September 30, 2026, alongside a net loss of $627 million. The company is looking to compete in the weight loss market, and it is running an oral phase 3 obesity trial.

Did Viking Move With Other Biotech Stocks?

Mostly not. Out of those 78 biotechnology companies, all worth $2 billion or more, 37 rose and 41 fell, and 3 rose 5% or more, as Viking did. The wider health care sector did better than the market, with the sector fund XLV gaining 0.5%.

Viking’s own peers gained far less, where they gained at all. Four of its five peers on the Trefis list rose, among them Eli Lilly, up 1.3%, and Altimmune, up 2.2%. Viking rose more than twice as much as any of them, so the stock moved largely on its own.

Big Rises Within A Losing Year For Viking

A rise this size is not unusual for Viking. The stock had 17 sessions in the prior 365 days with a rise at least this large, the latest an 8.0% gain on November 9, 2026. Three straight falls followed that gain before Friday’s rise.

The year has gone badly for holders. Over the twelve months to November 13, 2026, the stock returned -28.3%, against 11.7% for the S&P 500. It reached its highest close of that year, $42.13, on July 7, 2026, and fell to its lowest, $24.21, on October 26, 2026. Since October 15, the stock has returned 6.8% while the S&P 500 lost 2.3%, yet Friday’s close of $29.22 still sits much nearer the low than the high.

At Friday’s close, Viking was valued at about $3.4 billion, against $960 million of cash and short-term investments on September 30, 2026. The company will next report its fourth-quarter 2026 results, and the measure to watch is the cash its operations use, which was $138 million in the third quarter of 2026.

Want A Second Look At What You Own?

Viking Therapeutics is one decision in a portfolio. Whether you work with an advisor or manage your money yourself, a second look at the whole portfolio costs nothing. Our partner advisory firm offers a free written review of your holdings, fees and income plan, with no need to switch.

Get A Free Second Opinion

Spot an error or want more like this? Tell us in 10 seconds.